Search
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalLutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology. … Sugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals.
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.
Huperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnIt is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalIt works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Clomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Products: Clomid 50mg, Serophene Tab 50mgLarazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalCiglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. … Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.